Allen Lee Cohn
University of Southern California
151 Papers
1.1K Citations
Allen Lee Cohn is an academic researcher from University of Southern California. The author has contributed to research in topics: Bevacizumab & Medicine. The author has an hindex of 35, co-authored 142 publications.
Chat about Author
Papers
Abstract 5314: A proteomic signature predicts response to a therapeutic vaccine in pancreas cancer; analysis from the GI-4000-02 trial
Donald A. Richards,Peter Muscarella,Tanios Bekaii-Saab,Lalan S. Wilfong,Vic Velanovich,Julian Raynov,Patrick J. Flynn,William E. Fisher,Samuel H. Whiting,Constana Timcheva,Tom Holmes,Claire Coeshott,Alicia Mattson,Heinrich Roder,Joanna Roder,Allen Lee Cohn,Timothy C. Rodell +16 more
TL;DR: BDX-001 is a test developed using novel proteomic and learning theory methods that appears to predict treatment response to GI-4000 in resected pancreas cancer patients, potentially identifying patients with improved RFS and OS in the GI- 4000/gemcitabine arm.
2
570 Cabozantinib plus atezolizumab in advanced head and neck cancer previously treated with platinum-containing chemotherapy: Results from cohort 17 of the COSMIC-021 study
Sylvie Rottey,Armando Santoro,Suzanne V. Arnold,Saad M. Khan,Allen Lee Cohn,Bruno Fang,S. A. Andrianova,R. Sudhagoni,Leleesha Samaraweera,Maria Gonzalez-Cao +9 more
- 01 Nov 2022
TL;DR: COSMIC-021 (NCT03170960), a multicenter phase 1b study, is evaluating cabozantinib plus atezolizumab in advanced solid tumors; here they present outcomes in patients with platinum-pretreated advanced head and neck cancer (cohort 17).
Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study.
Udit Verma,Yull Edwin Arriaga,Heinz-Josef Lenz,Charles A. Henderson,Jyotsna Fuloria,Thomas H. Cartwright,Ali Khojasteh,Philip J. Stella,Marc Saltzman,Allen Lee Cohn,Philip A. Philip,Christian Kappeler,Joachim Kalmus,Axel Grothey,Eric Van Cutsem,Howard S. Hochster,Francis P. Arena +16 more
TL;DR: A retrospective subgroup analysis of patients enrolled in CONSIGN, a large phase IIIb study designed to provide continued access to regorafenib for patients with mCRC who failed standard therapy and to further characterize the safety of regorAFenib, finds adverse events and PFS were consistent with those reported in phase III studies.
1
Effectiveness of bevacizumab (BV) beyond disease progression in metastatic colorectal cancer (mCRC): Analyses by sex in the ARIES observational cohort study (OCS).
Allen Lee Cohn,Herbert Hurwitz,Tanios Bekaii-Saab,Johanna C. Bendell,Mark Kozloff,H. Tezcan,Elizabeth Dawn Flick,Yeung-Chul Mun,S. Fish,Darshan Dalal,Axel Grothey +10 more
TL;DR: This analysis was aimed at comparing the effectiveness of BV after 1st disease progression (PD) between male and female mCRC pts who received 1L BV-containing therapy in a real-world setting.
1
Second interim analysis of the Global Investigation of Therapeutic Decisions in Unresectable HCC and of Its Treatment with Sorafenib (GIDEON): Sorafenib dosing and safety in U.S. patients.
Anthony B. El-Khoueiry,Bilal Piperdi,Alec Goldenberg,Allen Lee Cohn,J.H. Geschwind,Jorge A. Marrero,Arun J. Sanyal,Alan P. Venook +7 more
TL;DR: While statistical comparisons were not made, PS or CP status may impact initial SOR dose selection andLimitations of an observational study must be considered, clinical judgment remains important in choosing initial S OR dose.
1